Hydrocodone Explained

Watchedfields:changed
Class:Opioid
Verifiedrevid:443251358
Width:200
Width2:225
Tradename:Hysingla ER, Zohydro ER
Dailymedid:Hydrocodone
Dependency Liability:High[1]
Addiction Liability:High
Routes Of Administration:Clinical: by mouth
Others: intranasal, rectal
Atc Prefix:R05
Atc Suffix:DA03
Legal Au:Schedule 8
Legal Br:A1
Legal Br Comment:[2]
Legal Ca:Schedule I
Legal De:Anlage III
Legal Nz:Class B
Legal Status:SE: Förteckning II
Legal Uk:Class A
Legal Us:Schedule II
Bioavailability:By mouth: 70%[3]
Protein Bound:Low[4]
Metabolism:Liver

CYP3A4 (major), CYP2D6 (minor)

Metabolites:• Norhydrocodone
• Hydromorphone
• Others
Onset:10–20 minutes
Elimination Half-Life:Average: 3.8 hours
Range: 3.3–4.4 hours
Duration Of Action:4–8 hours
Excretion:Urine[5] [6]
Cas Number:125-29-1
Pubchem:5284569
Chebi:5779
Chembl:1457
Chemspiderid:4447623
Drugbank:DB00956
Iuphar Ligand:7081
Kegg:D08045
Unii:6YKS4Y3WQ7
Synonyms:Dihydrocodeinone, hydrocodone bitartrate
Iupac Name:4,5α-epoxy-3-methoxy-17-methylmorphinan-6-one
C:18
H:21
N:1
O:3
Smiles:O=C4[C@@H]5Oc1c2c(ccc1OC)C[C@H]3N(CC[C@]25[C@H]3CC4)C
Stdinchi:1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1
Stdinchikey:LLPOLZWFYMWNKH-CMKMFDCUSA-N

Hydrocodone, also known as dihydrocodeinone, is a semisynthetic opioid used to treat pain and as a cough suppressant.[7] It is taken by mouth. Typically it is dispensed as the combination acetaminophen/hydrocodone or ibuprofen/hydrocodone for pain severe enough to require an opioid[8] [9] [10] and in combination with homatropine methylbromide to relieve cough. It is also available by itself in a long-acting form under the brand name Zohydro ER, among others, to treat severe pain of a prolonged duration.[11] Hydrocodone is a controlled drug: in the United States a Schedule II Controlled Substance.

Side effects and mechanisms

Common side effects include dizziness, sleepiness, nausea, and constipation.[7] Serious side effects may include low blood pressure, seizures, QT prolongation, respiratory depression, and serotonin syndrome.[7] Rapidly decreasing the dose may result in opioid withdrawal.[7] Use during pregnancy or breastfeeding is generally not recommended.[12] Hydrocodone is believed to work by activating opioid receptors, mainly in the brain and spinal cord.[7] Hydrocodone 10 mg is equivalent to about 10 mg of morphine by mouth.[13]

History and culture

Hydrocodone was patented in 1923, while the long-acting formulation was approved for medical use in the United States in 2013.[7] [14] It is most commonly prescribed in the United States, which consumed 99% of the worldwide supply as of 2010.[15] In 2018, it was the 402nd most commonly prescribed medication in the United States, with more than 400,000 prescriptions.[16] Hydrocodone is a semisynthetic opioid, converted from codeine[17] [18] or less often from thebaine.[19] Production using genetically engineered yeasts has been developed but is not used commercially.[20] [21] [22]

Medical uses

Hydrocodone is used to treat moderate to severe pain. In liquid formulations, it is used to treat cough.[7] In one study comparing the potency of hydrocodone to that of oxycodone, it was found that it took 50% more hydrocodone to achieve the same degree of miosis (pupillary contraction).[23] The investigators interpreted this to mean that oxycodone is about 50% more potent than hydrocodone.

However, in a study of emergency department patients with fractures, it was found that an equal amount of either drug provided about the same degree of pain relief, indicating that there is little practical difference between them when used for that purpose.[24] Some references state that the analgesic action of hydrocodone begins in 20–30 minutes and lasts about 4–8 hours.[25] The manufacturer's information says onset of action is about 10–30 minutes and duration is about 4–6 hours.[26] Recommended dosing interval is 4–6 hours. Hydrocodone reaches peak serum levels after 1.3 hours.[27]

Available forms

See also: Hydrocodone/paracetamol, Hydrocodone/ibuprofen and Hydrocodone/aspirin.

Hydrocodone is available in a variety of formulations for oral administration:[28] [29] [30]

Hydrocodone is not available in parenteral or any other non-oral forms.

Side effects

Common side effects of hydrocodone are nausea, vomiting, constipation, drowsiness, dizziness, lightheadedness, anxiety, abnormally happy or sad mood, dry throat, difficulty urinating, rash, itching, and contraction of the pupils. Serious side effects include slowed or irregular breathing and chest tightness.[32]

Several cases of progressive bilateral hearing loss unresponsive to steroid therapy have been described as an infrequent adverse reaction to hydrocodone/paracetamol misuse. This adverse effect has been considered by some to be due to the ototoxicity of hydrocodone.[33] [34] Other researchers have suggested that paracetamol is the primary agent responsible for the ototoxicity.[35] [36]

The U.S. Food and Drug Administration (FDA) assigns the drug to pregnancy category C, meaning that no adequate and well-controlled studies in humans have been conducted. A newborn of a mother taking opioid medications regularly prior to the birth will be physically dependent.[37] [38] The baby may also exhibit respiratory depression if the opioid dose was high. An epidemiological study indicated that opioid treatment during early pregnancy results in increased risk of various birth defects.[39]

Symptoms of hydrocodone overdose include narrowed or widened pupils; slow, shallow, or stopped breathing; slowed or stopped heartbeat; cold, clammy, or blue skin; excessive sleepiness; loss of consciousness; seizures; or death.

Hydrocodone can be habit forming, causing physical and psychological dependence. Its abuse liability is similar to morphine and less than oxycodone.[40]

Interactions

Hydrocodone is metabolized by the cytochrome P450 enzymes CYP2D6 and CYP3A4, and inhibitors and inducers of these enzymes can modify hydrocodone exposure.[41] One study found that combination of paroxetine, a selective serotonin reuptake inhibitor (SSRI) and strong CYP2D6 inhibitor, with once-daily extended-release hydrocodone, did not modify exposure to hydrocodone or the incidence of adverse effects.[42] These findings suggest that hydrocodone can be coadministered with CYP2D6 inhibitors without dosage modification. Conversely, combination of hydrocodone/acetaminophen with the antiviral regimen of ombitasvir, paritaprevir, ritonavir, and dasabuvir for treatment of hepatitis C increased peak concentrations of hydrocodone by 27%, total exposure by 90%, and elimination half-life from 5.1hours to 8.0hours.[43] Ritonavir is a strong CYP3A4 inhibitor as well as inducer of CYP3A and other enzymes, and the other antivirals are known to inhibit drug transporters like organic anion transporting polypeptide (OATP) 1B1 and 1B3, P-glycoprotein, and breast cancer resistance protein (BCRP). The changes in hydrocodone levels are consistent with CYP3A4 inhibition by ritonavir. Based on these findings, a 50% lower dose of hydrocodone and closer clinical monitoring was recommended when hydrocodone is used in combination with this antiviral regimen.

People consuming alcohol, other opioids, anticholinergic antihistamines, antipsychotics, anxiolytics, or other central nervous system (CNS) depressants together with hydrocodone may exhibit an additive CNS depression.[44] Hydrocodone taken concomitantly with serotonergic medications like SSRI antidepressants may increase the risk of serotonin syndrome.[45]

Pharmacology

Pharmacodynamics

Hydrocodone (and metabolite) at opioid receptors
Compound Affinities Ratio Ref
MOR:DOR:KOR
Hydrocodone 11.1 nM 962 nM 501 nM 1:87:45 [46]
0.47 nM 18.5 nM 24.9 nM 1:39:53 [47]

Equivalent analgesia doses[48] [49] [50]
Compound Dose
200 mg
Hydrocodone 20–30 mg
7.5 mg
1.5 mg
30 mg
10 mg
20 mg
10 mg
10 mg
1 mg

Hydrocodone is a highly selective full agonist of the μ-opioid receptor (MOR).[51] This is the main biological target of the endogenous opioid neuropeptide β-endorphin.[52] Hydrocodone has low affinity for the δ-opioid receptor (DOR) and the κ-opioid receptor (KOR), where it is an agonist similarly.

Studies have shown hydrocodone is stronger than codeine but only one-tenth as potent as morphine at binding to receptors and reported to be only 59% as potent as morphine in analgesic properties. However, in tests conducted on rhesus monkeys, the analgesic potency of hydrocodone was actually higher than morphine.[53] Oral hydrocodone has a mean equivalent daily dosage (MEDD) factor of 0.4, meaning that 1 mg of hydrocodone is equivalent to 0.4 mg of intravenous morphine. However, because of morphine's low oral bioavailability, there is a 1:1 correspondence between orally administered morphine and orally administered hydrocodone.[54]

Pharmacokinetics

Absorption

Hydrocodone is only pharmaceutically available as an oral medication. It is well-absorbed, but the oral bioavailability of hydrocodone is only approximately 25%. The onset of action of hydrocodone via this route is 10 to 20 minutes, with a peak effect (Tmax) occurring at 30 to 60 minutes, and it has a duration of 4 to 8 hours. The FDA label for immediate-release hydrocodone with acetaminophen does not include any information on the influence of food on its absorption or other pharmacokinetics.[55] Conversely, coadministration with a high-fat meal increases peak concentrations of different formulations of extended-release hydrocodone by 14 to 54%, whereas area-under-the-curve levels are not notably affected.[56] [57] [58] [59]

Distribution

The volume of distribution of hydrocodone is 3.3 to 4.7 L/kg. The plasma protein binding of hydrocodone is 20 to 50%.[25]

Metabolism

In the liver, hydrocodone is transformed into several metabolites, including norhydrocodone, hydromorphone, 6α-hydrocodol (dihydrocodeine), and 6β-hydrocodol.[60] 6α- and 6β-hydromorphol are also formed, and the metabolites of hydrocodone are conjugated (via glucuronidation).[61] [62] Hydrocodone has a terminal half-life that averages 3.8 hours (range 3.3–4.4 hours).[63] The hepatic cytochrome P450 enzyme CYP2D6 converts hydrocodone into hydromorphone, a more potent opioid (5-fold higher binding affinity to the MOR). However, extensive and poor cytochrome 450 CYP2D6 metabolizers had similar physiological and subjective responses to hydrocodone, and CYP2D6 inhibitor quinidine did not change the responses of extensive metabolizers, suggesting that inhibition of CYP2D6 metabolism of hydrocodone has no practical importance.[64] [65] Ultra-rapid CYP2D6 metabolizers (1–2% of the population) may have an increased response to hydrocodone; however, hydrocodone metabolism in this population has not been studied.[66]

Norhydrocodone, the major metabolite of hydrocodone, is predominantly formed by CYP3A4-catalyzed oxidation. In contrast to hydromorphone, it is described as inactive.[67] However, norhydrocodone is actually a MOR agonist with similar potency to hydrocodone, but has been found to produce only minimal analgesia when administered peripherally to animals (likely due to poor blood–brain barrier and thus central nervous system penetration).[68] Inhibition of CYP3A4 in a child who was, in addition, a poor CYP2D6 metabolizer, resulted in a fatal overdose of hydrocodone.[69] Approximately 40% of hydrocodone metabolism is attributed to non-cytochrome P450-catalyzed reactions.[70]

Elimination

Hydrocodone is excreted in urine, mainly in the form of conjugates.

Chemistry

Detection in body fluids

Hydrocodone concentrations are measured in blood, plasma, and urine to seek evidence of misuse, to confirm diagnoses of poisoning, and to assist in investigations into deaths. Many commercial opiate screening tests react indiscriminately with hydrocodone, other opiates, and their metabolites, but chromatographic techniques can easily distinguish hydrocodone uniquely. Blood and plasma hydrocodone concentrations typically fall into the 5–30 μg/L range among people taking the drug therapeutically, 100–200 μg/L among recreational users, and 100–1,600 μg/L in cases of acute, fatal overdosage. Co-administration of the drug with food or alcohol can very significantly increase the resulting plasma hydrocodone concentrations that are subsequently achieved.[71] [72]

Synthesis

Hydrocodone is most commonly synthesized from thebaine, a constituent of opium latex from the dried poppy plant. Once thebaine is obtained, the reaction undergoes hydrogenation using a palladium catalyst.[73]

Structure

There are three important structures in hydrocodone: the amine group, which binds to the tertiary nitrogen binding site in the central nervous system's opioid receptor, the hydroxy group that binds to the anionic binding side, and the phenyl group which binds to the phenolic binding site.[74] This triggers a G protein activation and subsequent release of dopamine.[75]

History

Hydrocodone was first synthesized in Germany in 1920 by Carl Mannich and Helene Löwenheim.[76] It was approved by the Food and Drug Administration on 23 March 1943 for sale in the United States and approved by Health Canada for sale in Canada under the brand name Hycodan.[77] [78]

Hydrocodone was first marketed by Knoll as Dicodid, starting in February 1924 in Germany. This name is analogous to other products the company introduced or otherwise marketed: Dilaudid (hydromorphone, 1926), Dinarkon (oxycodone, 1917), Dihydrin (dihydrocodeine, 1911), and Dimorphan (dihydromorphine). Paramorfan is the trade name of dihydromorphine from another manufacturer, as is Paracodin, for dihydrocodeine.[79] [80]

The name Dicodid was registered in the United States and appears without a monograph as late as 1978 in the Physicians' Desk Reference; Dicodid may have been marketed to one extent or another in North America in the 1920s and early 1930s. The drug was pure hydrocodone in small 5 and 10 mg tablets, physically similar to the Dilaudid tablets. It is no longer manufactured by Knoll in Germany, nor is a generic available. Hydrocodone was never as common in Europe as it is in North America—dihydrocodeine is used for its spectrum of indications. Germany was the number two consumer of hydrocodone until the manufacture of the drug was discontinued there. Now, the world outside the United States accounts for less than 1% of annual consumption. It was listed as a Suchtgift under the German Betäubungsmittelgesetz and regulated like morphine. It became available in the Schengen Area of the European Union as of 1 January 2002 under Title 76 of the Schengen Treaty.

Society and culture

Formulations

Several common imprints for hydrocodone are M365, M366, M367.[81]

Combination products

See main article: Hydrocodone/paracetamol and Hydrocodone/ibuprofen.

Most hydrocodone formulations include a second analgesic, such as paracetamol (acetaminophen) or ibuprofen. Examples of hydrocodone combinations include Norco, Vicodin, Vicoprofen and Riboxen.[82]

Legal status in the United States

The US government imposed tougher prescribing rules for hydrocodone in 2014, changing the drug from Schedule III to Schedule II.[83] [84] [85] [86] In 2011, hydrocodone products were involved in around 100,000 abuse-related emergency department visits in the United States, more than double the number in 2004.[87]

External links

Notes and References

  1. Book: Bonewit-West K, Hunt SA, Applegate E . Today's Medical Assistant: Clinical and Administrative Procedures . 2012 . 571 . Elsevier Health Sciences . 9781455701506 . 20 August 2019 . 10 January 2023 . https://web.archive.org/web/20230110030031/https://books.google.com/books?id=YalYPI1KqTQC&pg=PA571 . live .
  2. Web site: Anvisa . Brazilian Health Regulatory Agency . 31 March 2023 . RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial . Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control. live . https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 . 3 August 2023 . 16 August 2023 . . pt-BR . 4 April 2023.
  3. Book: Polsten GR, Wallace MS. Analgesic Agents in Rheumatic Disease. Firestein GS, Budd R, Gabriel SE, McInnes IB, O'Dell JR. Kelley and Firestein's Textbook of Rheumatology. https://books.google.com/books?id=kBZ6DAAAQBAJ&pg=PA1081. 21 June 2016. Elsevier Health Sciences. 978-0-323-41494-4. 1081–. 23 September 2016. 12 January 2023. https://web.archive.org/web/20230112203342/https://www.google.com/books/edition/Kelley_and_Firestein_s_Textbook_of_Rheum/kBZ6DAAAQBAJ?hl=en&gbpv=1&pg=PA1081&printsec=frontcover. live.
  4. Book: Chapter 37: Drug Therapy of Pain in Cancer Patients. Chabner BA, Longo DL. Cancer Chemotherapy and Biotherapy: Principles and Practice. https://books.google.com/books?id=WL4arNFsQa8C&pg=PA700. 8 November 2010. Lippincott Williams & Wilkins. 978-1-60547-431-1. 700–. 23 September 2016. 12 January 2023. https://web.archive.org/web/20230112203349/https://books.google.com/books?id=WL4arNFsQa8C&pg=PA700. live.
  5. Book: Bluth MH. Toxicology and Drug Testing, An Issue of Clinics in Laboratory Medicine, E-Book. 16 November 2016. Elsevier Health Sciences. 978-0-323-47795-6. 85–. 22 June 2018. 12 January 2023. https://web.archive.org/web/20230112203353/https://books.google.com/books?id=NAKRDQAAQBAJ&pg=PT85. live.
  6. Book: Smith HS. Opioid Therapy in the 21st Century. 21 February 2013. OUP USA. 978-0-19-984497-5. 68–. 22 June 2018. 12 January 2023. https://web.archive.org/web/20230112203347/https://books.google.com/books?id=MBxWFigSEE8C&pg=PT68. live.
  7. Web site: Hydrocodone Bitartrate Monograph for Professionals. 15 April 2019. Drugs.com. American Society of Health-System Pharmacists. 14 November 2010. https://web.archive.org/web/20101114074840/https://www.drugs.com/monograph/hydrocodone-bitartrate.html. live.
  8. Web site: Mallinckrodt. 10 March 2021. HYDROCODONE BITARTRATE AND ACETAMINOPHEN tablet (label). 6 November 2021. National Institutes of Health DailyMed. 6 November 2021. https://web.archive.org/web/20211106121028/https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73c1059b-0c7d-42ef-9827-f018858fc447. live.
  9. Book: Briggs GG, Freeman RK, Yaffe SJ . Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 2011. Lippincott Williams & Wilkins. 9781608317080. 692.
  10. Web site: Hydrocodone Combination Products: MedlinePlus Drug Information . 4 November 2023 . medlineplus.gov . en . 5 July 2016 . https://web.archive.org/web/20160705111552/https://www.nlm.nih.gov/medlineplus/druginfo/meds/a601006.html . live .
  11. Web site: Hydrocodone: MedlinePlus Drug Information. 15 April 2019. medlineplus.gov. 15 April 2019. https://web.archive.org/web/20190415183043/https://medlineplus.gov/druginfo/meds/a614045.html. live.
  12. Web site: Hydrocodone Use During Pregnancy . Drugs.com . 15 April 2019 . 28 January 2014 . https://web.archive.org/web/20140128132937/https://www.drugs.com/pregnancy/hydrocodone.html . live .
  13. Web site: Opioid Dose Calculator . Agency Medical Directors' Group . 15 April 2019 . 10 February 2016 . https://web.archive.org/web/20160210070737/http://www.agencymeddirectors.wa.gov/calculator/dosecalculator.htm . dead .
  14. Book: Fischer J, Ganellin CR . Analogue-based Drug Discovery . 2006 . John Wiley & Sons . 9783527607495 . 526 . 25 August 2020 . 14 January 2023 . https://web.archive.org/web/20230114010239/https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA526 . live .
  15. News: Making Some Painkillers Harder to Get . https://ghostarchive.org/archive/20220103/https://www.nytimes.com/2013/02/22/opinion/making-some-painkillers-harder-to-get.html . 3 January 2022 . subscription . live . 15 April 2019 . The New York Times . 21 February 2013.
  16. Web site: Hydrocodone - Drug Usage Statistics . ClinCalc . 7 October 2022 . 13 November 2022 . https://web.archive.org/web/20221113222415/https://clincalc.com/DrugStats/Drugs/Hydrocodone . live .
  17. Book: Stoker HS . General, Organic, and Biological Chemistry. 2012. Cengage Learning. 9781133711285. 567.
  18. Book: Vardanyan R, Hruby V . Synthesis of Essential Drugs. 10 March 2006. Elsevier. 978-0-08-046212-7. en.
  19. Book: Narcotic Drugs 2020, Estimated World Requirements for 2021, Statistics for 2019. International Narcotics Control Board. 2020. 978-92-1-148355-0. 37. Thebaine itself is not used in therapy, but it is an important starting material for the manufacture of a number of opioids, mainly codeine, dihydrocodeine, etorphine, hydrocodone, oxycodone and oxymorphone.... 12 December 2021. 3 November 2021. https://web.archive.org/web/20211103162923/https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2020/Narcotic_Drugs_Technical_publication_2020.pdf. live.
  20. Galanie S, Thodey K, Trenchard IJ, Filsinger Interrante M, Smolke CD . Complete biosynthesis of opioids in yeast . Science . 349 . 6252 . 1095–1100 . September 2015 . 26272907 . 4924617 . 10.1126/science.aac9373 . 2015Sci...349.1095G .
  21. Thodey K, Galanie S, Smolke CD . A microbial biomanufacturing platform for natural and semisynthetic opioids . Nature Chemical Biology . 10 . 10 . 837–844 . October 2014 . 25151135 . 4167936 . 10.1038/nchembio.1613 .
  22. Nakagawa A, Matsumura E, Koyanagi T, Katayama T, Kawano N, Yoshimatsu K, Yamamoto K, Kumagai H, Sato F, Minami H . 6 . Total biosynthesis of opiates by stepwise fermentation using engineered Escherichia coli . Nature Communications . 7 . 1 . 10390 . February 2016 . 26847395 . 4748248 . 10.1038/ncomms10390 . 2016NatCo...710390N .
  23. Zacny JP, Gutierrez S . Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers . Drug and Alcohol Dependence . 101 . 1–2 . 107–114 . April 2009 . 19118954 . 10.1016/j.drugalcdep.2008.11.013 . 25 August 2020 . 18 January 2021 . https://web.archive.org/web/20210118203050/https://zenodo.org/record/896375 . live .
  24. Marco CA, Plewa MC, Buderer N, Black C, Roberts A . Comparison of oxycodone and hydrocodone for the treatment of acute pain associated with fractures: a double-blind, randomized, controlled trial . Academic Emergency Medicine . 12 . 4 . 282–288 . April 2005 . 15805317 . 10.1197/j.aem.2004.12.005 . free .
  25. Vallejo R, Barkin RL, Wang VC . Pharmacology of opioids in the treatment of chronic pain syndromes . Pain Physician . 14 . 4 . E343–E360 . 2011 . 21785485 . 10.36076/ppj.2011/14/E343 . free .
  26. Web site: Opioid (Narcotic Analgesics and Acetaminophen Systemic) . 22 March 2014 . 22 March 2014 . https://web.archive.org/web/20140322074358/http://www.drugs.com/mmx/vicodin.html . dead .
  27. Web site: 18 October 2013 . Labeling-Package Insert: Hydrocodone/acetaminophen 7.5 mg/325 mg . 22 January 2024 . Drugs@FDA: FDA-Approved Drugs . Chartwell . 27 April 2024 . https://web.archive.org/web/20240427134028/https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/040432s006,40556s012,40658s006,%2040846s005,%2089699s044lbl.pdf . live .
  28. Book: McPherson ML. Appendix: Opioid Formulations. Demystifying Opioid Conversion Calculations: A Guide for Effective Dosing. https://books.google.com/books?id=6oBA9z5wl9wC&pg=PA187. 24 August 2009. ASHP. 978-1-58528-297-5. 187–188. 23 September 2016. 12 January 2023. https://web.archive.org/web/20230112203400/https://books.google.com/books?id=6oBA9z5wl9wC&pg=PA187. live.
  29. Book: Odom-Forren J, Drain C. PeriAnesthesia Nursing: A Critical Care Approach. 11 February 2008. Elsevier Health Sciences. 978-1-4377-2610-7. 751–. 23 September 2016. 12 January 2023. https://web.archive.org/web/20230112203347/https://books.google.com/books?id=2DxxrrJafncC&pg=PT751. live.
  30. Book: Skidmore-Roth L. Hydrocodone. Mosby's Drug Guide for Nursing Students, with 2014 Update. https://books.google.com/books?id=r71EBAAAQBAJ&pg=PA524. 27 June 2013. Elsevier Health Sciences. 978-0-323-22268-6. 524–. 23 September 2016. 12 January 2023. https://web.archive.org/web/20230112203414/https://books.google.com/books?id=r71EBAAAQBAJ&pg=PA524. live.
  31. Vadivelu N, Schermer E, Kodumudi G, Berger JM . The Clinical Applications of Extended-Release Abuse-Deterrent Opioids . CNS Drugs . 30 . 7 . 637–646 . July 2016 . 27290716 . 10.1007/s40263-016-0357-0 . 26878027 .
  32. Web site: Hydrocodone Combination Products . MedlinePlus . U.S. National Library of Medicine . 1 October 2008 . 20 April 2013 . 5 July 2016 . https://web.archive.org/web/20160705111552/https://www.nlm.nih.gov/medlineplus/druginfo/meds/a601006.html . live .
  33. Friedman RA, House JW, Luxford WM, Gherini S, Mills D . Profound hearing loss associated with hydrocodone/acetaminophen abuse . The American Journal of Otology . 21 . 2 . 188–191 . March 2000 . 10733182 . 10.1016/S0196-0709(00)80007-1 . 31 January 2024 .
  34. Ho T, Vrabec JT, Burton AW . Hydrocodone use and sensorineural hearing loss . Pain Physician . 10 . 3 . 467–472 . May 2007 . 17525781 . dead . https://web.archive.org/web/20110723082234/http://www.painphysicianjournal.com/linkout_vw.php?issn=1533-3159&vol=10&page=467 . 23 July 2011 .
  35. Yorgason JG, Kalinec GM, Luxford WM, Warren FM, Kalinec F . Acetaminophen ototoxicity after acetaminophen/hydrocodone abuse: evidence from two parallel in vitro mouse models . Otolaryngology–Head and Neck Surgery . 142 . 6 . 814–9, 819.e1–2 . June 2010 . 20493351 . 10.1016/j.otohns.2010.01.010 . 25083914 .
  36. Curhan SG, Eavey R, Shargorodsky J, Curhan GC . Analgesic use and the risk of hearing loss in men . The American Journal of Medicine . 123 . 3 . 231–237 . March 2010 . 20193831 . 2831770 . 10.1016/j.amjmed.2009.08.006 .
  37. Web site: Neonatal abstinence syndrome: MedlinePlus Medical Encyclopedia. 11 January 2022. medlineplus.gov. en. 28 July 2017. https://web.archive.org/web/20170728061943/https://medlineplus.gov/ency/article/007313.htm. live.
  38. Web site: Opioid Use and Opioid Use Disorder in Pregnancy. 11 January 2022. www.acog.org. en. 11 January 2022. https://web.archive.org/web/20220111225403/https://www.acog.org/en/clinical/clinical-guidance/committee-opinion/articles/2017/08/opioid-use-and-opioid-use-disorder-in-pregnancy. live.
  39. Broussard CS, Rasmussen SA, Reefhuis J, Friedman JM, Jann MW, Riehle-Colarusso T, Honein MA . Maternal treatment with opioid analgesics and risk for birth defects . American Journal of Obstetrics and Gynecology . 204 . 4 . 314.e1–314.11 . April 2011 . 21345403 . 10.1016/j.ajog.2010.12.039 . free .
  40. Wightman R, Perrone J, Portelli I, Nelson L . Likeability and abuse liability of commonly prescribed opioids . Journal of Medical Toxicology . 8 . 4 . 335–340 . December 2012 . 22992943 . 3550270 . 10.1007/s13181-012-0263-x .
  41. Feng XQ, Zhu LL, Zhou Q . Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management . Journal of Pain Research . 10 . 1225–1239 . 2017 . 28579821 . 5449157 . 10.2147/JPR.S138698 . free .
  42. Kapil RP, Friedman K, Cipriano A, Michels G, Shet M, Mondal SA, Harris SC . Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet . Clinical Therapeutics . 37 . 10 . 2286–2296 . October 2015 . 26350273 . 10.1016/j.clinthera.2015.08.007 . free .
  43. Polepally AR, King JR, Ding B, Shuster DL, Dumas EO, Khatri A, Chiu YL, Podsadecki TJ, Menon RM . 6 . Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers . Clinical Pharmacokinetics . 55 . 8 . 1003–1014 . August 2016 . 26895022 . 4933729 . 10.1007/s40262-016-0373-8 .
  44. Web site: REPREXAIN (hydrocodone bitartrate, ibuprofen) tablet, film coated . dailymed.nlm.nih.gov . NIH . 27 April 2013 . 6 July 2013 . https://web.archive.org/web/20130706022619/http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7b71e4c3-86f2-464a-b0a9-4f98adfef9c5 . live .
  45. Gnanadesigan N, Espinoza RT, Smith RL . The serotonin syndrome . The New England Journal of Medicine . 352 . 23 . 2454–6; author reply 2454–6 . June 2005 . 15948273 . 10.1056/NEJM200506093522320 .
  46. Codd EE, Shank RP, Schupsky JJ, Raffa RB . Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception . The Journal of Pharmacology and Experimental Therapeutics . 274 . 3 . 1263–1270 . September 1995 . 7562497 . 21 June 2018 . 2 February 2017 . https://web.archive.org/web/20170202020241/http://jpet.aspetjournals.org/content/274/3/1263.short . live .
  47. Filizola M, Villar HO, Loew GH . Molecular determinants of non-specific recognition of delta, mu, and kappa opioid receptors . Bioorganic & Medicinal Chemistry . 9 . 1 . 69–76 . January 2001 . 11197347 . 10.1016/S0968-0896(00)00223-6 .
  48. Book: King TL, Miller EL . Analgesia and Anesthesia . King TL, Brucker MC . Pharmacology for Women's Health. https://books.google.com/books?id=o_rHHCsIpckC&pg=PA332. 25 October 2010. Jones & Bartlett Publishers. 978-1-4496-1073-9. 332–.
  49. Book: Parker RK, Hepner D, Eappin S. Chapter 27 Postoperative and Chronic Pain: Systemic and Regional Analgesic Techniques. Chestnut DH, Wong CA, Tsen LC, Kee WD, Beilin Y, Mhyre J. Chestnut's Obstetric Anesthesia: Principles and Practice E-Book. https://books.google.com/books?id=FMU0AwAAQBAJ&pg=PA611. 28 February 2014. Elsevier Health Sciences. 978-0-323-11374-8. 611–. 22 June 2018. 11 January 2023. https://web.archive.org/web/20230111005540/https://books.google.com/books?id=FMU0AwAAQBAJ&pg=PA611. live.
  50. Book: Tiziani AP. Opiod Analgesics. Havard's Nursing Guide to Drugs. https://books.google.com/books?id=XpzQAgAAQBAJ&pg=PA933. 1 June 2013. Elsevier Health Sciences. 978-0-7295-8162-2. 933–. 22 June 2018. 11 January 2023. https://web.archive.org/web/20230111005617/https://books.google.com/books?id=XpzQAgAAQBAJ&pg=PA933. live.
  51. Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE . Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors . The Journal of Pharmacology and Experimental Therapeutics . 308 . 2 . 547–554 . February 2004 . 14600248 . 10.1124/jpet.103.058602 . 22492018 .
  52. Book: Agar M, Clark K . Palliative Medicine . Talley NJ, Frankum B, Currow D . Essentials of Internal Medicine . 3rd . https://books.google.com/books?id=0Zq9BwAAQBAJ&pg=PA491. 10 February 2015. Elsevier Health Sciences. 978-0-7295-8081-6. 491–.
  53. Book: Davis MP, Glare P, Hardy J . Opioids in Cancer Pain. 2005. Oxford University Press. 978-0-19-852943-9. 59–68.
  54. Web site: Instructions for Mean Equivalent Daily Dose (MEDD) . 22 August 2010 . dead . https://web.archive.org/web/20110727162622/http://www.palliative.org/PC/ClinicalInfo/AssessmentTools/MeanEquivalent%20for%20program%20v3.pdf . 27 July 2011 .
  55. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/040099s023lbl.pdf Hydrocodone Bitartrate and Acetaminophen Tablets, USP 5 mg/325 mg CII
  56. Raffa RB, Colucci R, Pergolizzi JV . The effects of food on opioid-induced nausea and vomiting and pharmacological parameters: a systematic review . Postgraduate Medicine . 129 . 7 . 698–708 . September 2017 . 28635354 . 10.1080/00325481.2017.1345282 . 46184629 .
  57. Bond M, Rabinovich-Guilatt L, Selim S, Darwish M, Tracewell W, Robertson P, Yang R, Malamut R, Colucci P, Ducharme MP, Spiegelstein O . 6 . Effect of Food on the Pharmacokinetics of Single- and Multiple-Dose Hydrocodone Extended Release in Healthy Subjects . Clinical Drug Investigation . 37 . 12 . 1153–1163 . December 2017 . 28948482 . 10.1007/s40261-017-0575-3 . 32440860 .
  58. Farr SJ, Robinson CY, Rubino CM . Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers . Clinical Pharmacology . 7 . 1–9 . 2015 . 25653563 . 4307648 . 10.2147/CPAA.S70831 . free .
  59. Devarakonda K, Kostenbader K, Giuliani MJ, Young JL . Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) under fed and fasted conditions: two randomized open-label trials . BMC Pharmacology & Toxicology . 16 . 31 . November 2015 . 26614499 . 4662814 . 10.1186/s40360-015-0032-y . free .
  60. Book: Zhou S . Substrates of Human CYP2D6: Opioids and Opioid Receptor Antagonists . Cytochrome P450 2D6: Structure, Function, Regulation and Polymorphism. https://books.google.com/books?id=UJqmCwAAQBAJ&pg=PA164. 6 April 2016. CRC Press. 978-1-4665-9788-4. 164–.
  61. Book: Jenkins AJ. Pharmacokinetics of Specific Drugs. Karch SB. Pharmacokinetics and Pharmacodynamics of Abused Drugs. https://books.google.com/books?id=9fwUQvF4r-cC&pg=PA56. 9 October 2007. CRC Press. 978-1-4200-5460-6. 56–. 23 September 2016. 12 January 2023. https://web.archive.org/web/20230112203401/https://books.google.com/books?id=9fwUQvF4r-cC&pg=PA56. live.
  62. Book: Broussard LA . Challenges in Confirmation Testing for Drugs of Abuse . Dasgupta A, Sepulveda JL . Accurate Results in the Clinical Laboratory: A Guide to Error Detection and Correction. https://books.google.com/books?id=HEBloh3nxiAC&pg=PA239. 22 January 2013. Newnes. 978-0-12-415858-0. 239–.
  63. Book: Elliott JA . Opioids in the management of acute pain . Elliott JA, Smith HS . Handbook of Acute Pain Management. https://books.google.com/books?id=Em7OBQAAQBAJ&pg=PA79. 19 April 2016. CRC Press. 978-1-4665-9635-1. 79–.
  64. Kaplan HL, Busto UE, Baylon GJ, Cheung SW, Otton SV, Somer G, Sellers EM . Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability . The Journal of Pharmacology and Experimental Therapeutics . 281 . 1 . 103–108 . April 1997 . 9103485 .
  65. Gardiner SJ, Begg EJ . Pharmacogenetics, drug-metabolizing enzymes, and clinical practice . Pharmacological Reviews . 58 . 3 . 521–590 . September 2006 . 16968950 . 10.1124/pr.58.3.6 . 25747320 .
  66. Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, Kharasch ED, Skaar TC . 6 . Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype . Clinical Pharmacology and Therapeutics . 91 . 2 . 321–326 . February 2012 . 22205192 . 3289963 . 10.1038/clpt.2011.287 .
  67. Book: Sepulveda JL. Genetic Aspect of Opiate Metabolism and Addiction. Dasgupta A, Langman LJ. Pharmacogenomics of Alcohol and Drugs of Abuse. https://books.google.com/books?id=AiHaRjs3grYC&pg=PA175. 23 April 2012. CRC Press. 978-1-4398-5611-6. 175–. 23 September 2016. 12 January 2023. https://web.archive.org/web/20230112203403/https://books.google.com/books?id=AiHaRjs3grYC&pg=PA175. live.
  68. Navani DM, Yoburn BC . In vivo activity of norhydrocodone: an active metabolite of hydrocodone . The Journal of Pharmacology and Experimental Therapeutics . 347 . 2 . 497–505 . November 2013 . 23995596 . 10.1124/jpet.113.207548 . 31072872 .
  69. Madadi P, Hildebrandt D, Gong IY, Schwarz UI, Ciszkowski C, Ross CJ, Sistonen J, Carleton BC, Hayden MR, Lauwers AE, Koren G . 6 . Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions . Pediatrics . 126 . 4 . e986–e989 . October 2010 . 20837591 . 10.1542/peds.2009-1907 . 42365304 .
  70. Vuilleumier PH, Stamer UM, Landau R . Pharmacogenomic considerations in opioid analgesia . Pharmacogenomics and Personalized Medicine . 5 . 73–87 . 2012 . 23226064 . 3513230 . 10.2147/PGPM.S23422 . free .
  71. Spiller HA . Postmortem oxycodone and hydrocodone blood concentrations . Journal of Forensic Sciences . 48 . 2 . 429–431 . March 2003 . 12665006 . 10.1520/JFS2002309 .
  72. Book: Baselt RC . Disposition of Toxic Drugs and Chemicals in Man. 2017. Biomedical Publications. 978-0-692-77499-1. 1050–1052.
  73. Carroll RJ, Leisch H, Rochon L, Hudlicky T, Cox DP . One-pot conversion of thebaine to hydrocodone and synthesis of neopinone ketal . The Journal of Organic Chemistry . 74 . 2 . 747–752 . January 2009 . 19072148 . 10.1021/jo802454v .
  74. Book: Sinatra RS . The Essence of Analgesia and Analgesics . 6 December 2010. Cambridge University Press . Cambridge . 9780511841378 . 73, 81 .
  75. Book: Cruz SL . Neuroscience in the 21st Century . 27 October 2016 . Springer . New York, NY . 978-1-4939-3474-4 . 3626, 3657 .
  76. Mannich C, Löwenheim H. Ueber zwei neue Reduktionsprodukte des Kodeins. Archiv der Pharmazie. 258. 2–4. 1920. 295–316. 0365-6233. 10.1002/ardp.19202580218. 97513395. 12 September 2019. 1 August 2020. https://web.archive.org/web/20200801170102/https://zenodo.org/record/1424591. live.
  77. Web site: Drugs@FDA—Approval History: Hycodan . 7 January 2006 . FDA . 28 August 2021 . https://web.archive.org/web/20210828113415/https://www.accessdata.fda.gov/scripts/cder/daf/ . live .
  78. Web site: FDA Docket No. 2007N-0353, Drug Products Containing Hydrocodone; Enforcement Action Dates . 7 January 2006 . FDA . 12 January 2008 . https://web.archive.org/web/20080112075758/http://www.fda.gov/OHRMS/DOCKETS/98fr/E7-19340.htm . live . See section I. B., DESI Review of Hydrocodone Products
  79. Web site: PubChem. Dihydromorphine. 21 May 2021. U.S. National Library of Medicine. en. 14 July 2014. https://web.archive.org/web/20140714124655/http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5359421&loc=ec_rcs. live.
  80. Web site: PubChem. Dihydrocodeine. 21 May 2021. U.S. National Library of Medicine. 21 May 2021. https://web.archive.org/web/20210521140907/https://pubchem.ncbi.nlm.nih.gov/compound/5284543. live.
  81. Book: International Narcotics Control Board Report 2008. 2009. United Nations Pubns. 978-9211482324. 20.
  82. Web site: Hydrocodone Combination Products . MedlinePlus . The American Society of Health-System Pharmacists, Inc. . 14 July 2018 . 5 July 2016 . https://web.archive.org/web/20160705111552/https://www.nlm.nih.gov/medlineplus/druginfo/meds/a601006.html . live .
  83. McCarthy M . Prescriptions for hydrocodone plummet after US tightens prescribing rules . BMJ . 352 . i549 . January 2016 . 26819247 . 10.1136/bmj.i549 . 45954090 .
  84. Jones CM, Lurie PG, Throckmorton DC . Effect of US Drug Enforcement Administration's Rescheduling of Hydrocodone Combination Analgesic Products on Opioid Analgesic Prescribing . JAMA Internal Medicine . 176 . 3 . 399–402 . March 2016 . 26809459 . 10.1001/jamainternmed.2015.7799 . free .
  85. Chambers J, Gleason RM, Kirsh KL, Twillman R, Webster L, Berner J, Fudin J, Passik SD . 6 . An Online Survey of Patients' Experiences Since the Rescheduling of Hydrocodone: The First 100 Days . Pain Medicine . 17 . 9 . 1686–1693 . September 2016 . 26814291 . 10.1093/pm/pnv064 . free .
  86. News: Schedules of Controlled Substances: Rescheduling of Hydrocodone Combination Products From Schedule III to Schedule II. 22 August 2014. Federal Register. 11 August 2017. 11 August 2017. https://web.archive.org/web/20170811183529/https://www.federalregister.gov/documents/2014/08/22/2014-19922/schedules-of-controlled-substances-rescheduling-of-hydrocodone-combination-products-from-schedule. live.
  87. Web site: Drug-Related Hospital Emergency Room Visits . National Institute on Drug Abuse . 11 August 2017 . 11 August 2017 . https://web.archive.org/web/20170811183636/https://www.drugabuse.gov/publications/drugfacts/drug-related-hospital-emergency-room-visits . live .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Hydrocodone".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.